Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on February 28, 2020, regarding events occurring on February 26, 2020. The filing addresses corporate governance changes, specifically the election of a new director and the adjustment of Board composition.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- Director Election: Richard Paulson, 52, was elected as a director and designated as a Class II director with a term expiring at the 2021 annual meeting.
- Committee Assignment: Mr. Paulson was appointed to the Compensation Committee.
- Class II Adjustment: The number of Class II directors increased from one to two.
Compensation and Governance Details
Mr. Paulson's compensation package includes:
- Cash Retainer: $40,000 annual cash retainer for Board service and $7,500 for Compensation Committee service, prorated from the appointment date to the 2020 annual meeting.
- Equity Grant: An option to purchase 50,000 shares of common stock at the closing price on the grant date.
- Vesting Schedule: One-third of shares vest on the first anniversary; the remainder vests monthly (1/36th per month) over the subsequent two years, contingent on continued service.
- Indemnification: An indemnification agreement was executed, requiring the Company to indemnify Mr. Paulson for expenses and liabilities arising from his service as a director.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 50,000 share option granted to Mr. Paulson.
- Confirm the total number of outstanding options and warrants to assess potential dilution from this new grant.
- Review the Company's most recent 10-K or 10-Q for current cash balances to ensure liquidity supports the new cash retainer obligations.
- Check for any related party transactions involving Mr. Paulson not disclosed in this filing.